Translational research with topical calcineurin inhibitors in early MF

Introduction and aims: Activation of calcineurin signaling pathway is found in about 50% of human MF cases. Our phase II, multicentric, single arm, clinical trial with topical calcineurin inhibitors (TCIs) in early MF patients demonstrated an overall response rate of 56.4% to pimecrolimus 10  mg/g cream.

Source: European Journal of Cancer - August 29, 2018 Category: Cancer & Oncology Authors: Lidia Maro ñas-Jiménez, Teresa Estrach, Cristina Muniesa, Ricardo Fernández de Misa, Onofre San martín, Fernando Gallardo, Blanca Jiménez, May Sanchez-Beato, Laura Cereceda, J.P. Vaqué, M.A. Piris, Pablo Ortiz-Romero Source Type: research